330187-55-8

Basic information

• Product Name: (9H-Fluoren-9-yl)methyl(tert-butoxycarbonyl)methylformylmethyl carbamate
• CAS NO: 330187-55-8
• Molecular Weight: 395.455
• Mol File: 330187-55-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (9H-Fluoren-9-yl)methyl(tert-butoxycarbonyl)methylformylmethyl carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (9H-Fluoren-9-yl)methyl(tert-butoxycarbonyl)methylformylmethyl carbamate(330187-55-8)
• EPA Substance Registry System: (9H-Fluoren-9-yl)methyl(tert-butoxycarbonyl)methylformylmethyl carbamate(330187-55-8)

Safety Data

• Hazardous Substances Data: 330187-55-8(Hazardous Substances Data)

Usage

Description

(9H-Fluoren-9-yl)methyl(tert-butoxycarbonyl)methylformylmethyl carbamate is a complex organic molecule with a fluorene group linked to a formylmethyl carbamate group, which is further connected to a tert-butoxycarbonyl group. The fluorene group is a polycyclic aromatic hydrocarbon, while the formylmethyl carbamate group contains a carbonyl functional group and a carbamate functional group. The tert-butoxycarbonyl group serves as a protecting group in organic synthesis, preventing unwanted reactions. (9H-Fluoren-9-yl)methyl(tert-butoxycarbonyl)methylformylmethyl carbamate is expected to have diverse applications in organic synthesis and pharmaceutical chemistry due to its unique structure and functional groups.

Uses

Used in Organic Synthesis:
(9H-Fluoren-9-yl)methyl(tert-butoxycarbonyl)methylformylmethyl carbamate is used as an intermediate in organic synthesis for the creation of various complex molecules. Its fluorene and formylmethyl carbamate groups provide a versatile platform for further chemical reactions and modifications.
Used in Pharmaceutical Chemistry:
In the pharmaceutical industry, (9H-Fluoren-9-yl)methyl(tert-butoxycarbonyl)methylformylmethyl carbamate is used as a building block for the development of new drugs. The presence of the fluorene group and the carbamate functional group allows for the design of molecules with potential biological activities, targeting specific receptors or enzymes in the body.
Used in Drug Delivery Systems:
(9H-Fluoren-9-yl)methyl(tert-butoxycarbonyl)methylformylmethyl carbamate can be employed in the development of drug delivery systems, where its functional groups can be utilized to enhance the solubility, stability, and targeted delivery of therapeutic agents.
Used in Chemical Research:
(9H-Fluoren-9-yl)methyl(tert-butoxycarbonyl)methylformylmethyl carbamate is also used in chemical research as a model system to study the reactivity and properties of fluorene and carbamate groups, as well as the effects of the tert-butoxycarbonyl protecting group on the overall molecule's behavior in various chemical reactions.

Upstream product

• 6456-74-2 Glycine tert-butyl ester 
• 1353744-92-9 (9H-fluoren-9-yl)methyl(tert-butoxycarbonyl)methyl 2,3-dihydroxypropylcarbamate 
• 1353744-91-8 tert-butyl 2-(2,3-dihydroxypropylamino)acetate 
• 141743-16-0 N-(carboxymethyl)-N-Fmoc-glycine tert-butyl ester 
• 330187-54-7 N-(S-ethyl-thiocarbonylmethyl)-N-Fmoc-glycine tert-butyl ester 

Downstream Products

• 330187-62-7 N-{2-[benzyloxycarbonylacetyl-(1-carbamoyl-2-phenyl-ethyl)-amino]-ethyl}-3-benzyloxycarbonylamino-N-tert-butoxycarbonylmethyl-succinamic acid cyclohexyl ester 
• 330187-60-5 2(S)-[N-[2-[N'-(9-fluorenylmethoxycarbonyl)-N'-(tert-butyloxycarbonylmethyl)]aminoethyl]-N-[(1',3'-dioxo-3'-benzyloxy)propyl]]-2-amino-3-phenylpropionamide 
• 446880-45-1 3-amino-N-tert-butoxycarbonylmethyl-N-{2-[(1-carbamoyl-2-phenyl-ethyl)-carboxyacetyl-amino]-ethyl}-succinamic acid cyclohexyl ester 
• 330187-64-9 [(S)-1-((S)-1-Carbamoyl-2-phenyl-ethyl)-6-cyclohexyloxycarbonylmethyl-5,8,10-trioxo-[1,4,7]triazecan-4-yl]-acetic acid tert-butyl ester 
• 446880-48-4 [(S)-1-((S)-1-Acetylamino-2-phenyl-ethyl)-6-cyclohexyloxycarbonylmethyl-5,8,10-trioxo-[1,4,7]triazecan-4-yl]-acetic acid tert-butyl ester 
• 446880-50-8 [(S)-7-((S)-1-Amino-2-phenyl-ethyl)-4-tert-butoxycarbonylmethyl-3,8,10-trioxo-[1,4,7]triazecan-2-yl]-acetic acid cyclohexyl ester 
• 446880-44-0 2(S)-[N-[2-[N'-(tert-butyloxycarbonylmethyl)]aminoethyl]-N-[(1',3'-dioxo-3'-benzyloxy)propyl]]-2-amino-3-phenylpropionamide 
• 330187-58-1 3-phenyl-1(S)-[[2'-[N''-(9-fluorenylmethoxycarbonyl)-N''-(tert-butyloxycarbonylmethyl)]amino]ethylamino]propionamide 

Relevant articles and documents

Kras inhibitory cyclic peptide compound

The following were discovered: a cyclic peptide compound that interacts with Ras; and an unnatural amino acid that is useful in the production of said cyclic peptide compound. The cyclic peptide compound was also discovered to inhibit bonding between Ras and SOS. The following were additionally discovered: a specific unnatural amino acid included in said cyclic peptide compound; and a manufacturing method therefor.

Ni-to-Ni + 3-ethylene-bridged partially modified retro-inverso tetrapeptide β-turn mimetic: Design, synthesis, and structural characterizationt

A 10-membered heterocyclic ring system 1,3,8-trisubstituted 2,5,7-trioxo-1,4,8-triazadecane that represents a Ni-to-Ni + 3-ethylene-bridged partially modified retro-inverso tetrapeptide β-turn mimetic (EBRIT-BTM) has been designed, synthesized, and structurally analyzed. These compounds utilize an ethylene bridge to replace the COi · · · HNi + 3 10-membered hydrogen bond of standard β-turns. The N, N'-ethylene-bridged dimer was obtained in 90% yield by reductive alkylation of phenylalanylamide with a tert-butyl N-(9-fluorenylmethyloxycarbonyl), N-(2-formylmethyl)-glycinate. An orthogonal protection strategy and HATU-mediated couplings allowed efficient stepwise additions of monomeric building blocks leading to a Ni-to-Ni+3-ethylene-bridged linear precursor: H-Asp-(OcHex)-NGly-OBut HO2CCH2CO-NPhe-NH2. Further elaboration of the linear precursor generated the ethylene-bridged model compounds H2N-rPheN-mGly-Asp-NGly-OH (16) and Ac-gPheN-mGly-Asp-NGly-OH (18) (g, gem-diaminoalkyl; m, malonyl; and r, direction-reversed amino acid residue) in 44 and 39% yields, respectively. The structural features of the two EBRIT-BTM compounds were determined using 1H NMR and extensive computer simulations. The results indicate that the 10-membered rings are conformationally constrained with well-defined structural features and that the three amide bonds in the ring are in the trans orientation. The topological arrangement of the residues in the ring system closely resembles a type II' β-turn. Transformation of CONH2 in the N-terminal amino acid residue of 16 into NHCOCH3 in 18 resulted in the formation of a hydrogen bond between the NH ofgPhe-COCH3 and the C-terminal carboxyl of Gly, initiating an antiparallel β-sheet. The formulation of the concept applying a minimalistic structural elaboration approach and the synthetic exploration, together with the conformational analysis, offer a new molecular scaffolding system and a true tetrapeptide secondary structure mimetic that can be used to generate peptidomimetics of biological interest.